Philogen is an integrated biotechnology firm based in Switzerland and Italy, established in 1996. Its goal is to create novel biopharmaceuticals for the management of disorders related to the growth of new blood vessels (angiogenesis). Angiogenesis is a defining characteristic of various serious conditions including cancer, rheumatoid arthritis, and age-related macular degeneration. The company has been at the forefront of identifying, modifying, and clinically advancing leading products that target angiogenesis in living organisms. Philogen has also achieved the distinction of being the first to prove the efficacy of human monoclonal antibodies specific to an angiogenesis marker.